Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Aberdeen Group plc increased its stake in NewAmsterdam Pharma by 10.2% to 729,484 shares valued at $25.59 million, while institutional investors collectively own about 89.89% of the company.
• Company insiders have sold heavily — a total of 1,313,286 shares worth $42.96 million over the past three months — cutting insider ownership to 20.84%.
• Analysts are broadly positive with a consensus Moderate Buy and a $48 target, but NewAmsterdam recently missed quarterly EPS estimates and faces negative profitability (expected -1.75 EPS for the year).

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 729,484 shares of the company's stock after purchasing an additional 67,538 shares during the period. Aberdeen Group plc owned about 0.64% of NewAmsterdam Pharma worth $25,590,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Frazier Life Sciences Management L.P. grew its stake in shares of NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company's stock valued at $300,754,000 after buying an additional 490,656 shares in the last quarter. Capital World Investors raised its position in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company's stock worth $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. Jennison Associates LLC raised its position in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company's stock worth $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Wellington Management Group LLP lifted its stake in NewAmsterdam Pharma by 21.0% in the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company's stock valued at $114,332,000 after acquiring an additional 697,129 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the period. Institutional investors own 89.89% of the company's stock.

Analyst Upgrades and Downgrades

NAMS has been the topic of a number of research analyst reports. Leerink Partners reaffirmed an "outperform" rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Stifel Nicolaus boosted their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, December 16th. Needham & Company LLC upped their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, February 18th. Truist Financial began coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a "buy" rating and a $57.00 price objective for the company. Finally, Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.00.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 39,816 shares of the business's stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $32.62, for a total value of $1,298,797.92. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company's stock, valued at $794,394.86. The trade was a 62.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the sale, the insider directly owned 69,302 shares of the company's stock, valued at $2,099,850.60. This represents a 60.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,313,286 shares of company stock worth $42,963,764 over the last three months. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $32.99 on Monday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of -19.07 and a beta of 0.13. The business's fifty day moving average price is $32.35 and its two-hundred day moving average price is $34.07.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.